Company Overview: Cesca Therapeutics

Industry News

2 Mar

Cesca Therapeutics Announces 1-for-20 Reverse Split of Common Stock

Stockholders Approve Reverse Split RANCHO CORDOVA, Calif., March 02, 2016 (GLOBE NEWSWIRE) — Cesca Therapeutics Inc. (KOOL), an autologous cell-based regenerative medicine company, today announced stockholder approval of a reverse split of Cesca Therapeutics Inc Common Stock at the annual meeting of stockholders.  With stockholder approval, the Cesca Therapeutics...

Read more

11 Feb

Cesca Therapeutics to Announce Second Quarter Fiscal 2016 Results and Provide a Status Update to Investors on February 16, 2016

RANCHO CORDOVA, Calif., Feb. 11, 2016 (GLOBE NEWSWIRE) — Cesca Therapeutics Inc. (KOOL), an autologous cell-based regenerative medicine company, today announced that it will report financial results for the fiscal second quarter ended December 31, 2015 and provide a status update to investors on Tuesday, February 16, 2016. Company’s Conference...

Read more

9 Feb

Texas Stem Cell Enters Into an Agreement With Cesca Therapeutics for Use of AutoXpress® Technology for Cord Blood Processing

RANCHO CORDOVA, Calif. and HOUSTON, Feb. 09, 2016 (GLOBE NEWSWIRE) — Cesca Therapeutics Inc. (KOOL), an autologous cell-based regenerative medicine company, today announced that Texas Stem Cell has committed to utilizing Cesca’s AutoXpress® AXP technology for its cord blood banking business. The AXP platform includes a ‘smart’ processing device...

Read more

3 Feb

Cesca Announces $15 Million Strategic Investment From Boyalife Group

Funds to be Used to Repay Current Senior Secured Convertible Debentures and Provide Additional Working Capital to Fund Ongoing Operations and Strategic Initiatives RANCHO CORDOVA, Calif., Feb. 03, 2016 (GLOBE NEWSWIRE) — Cesca Therapeutics Inc. (KOOL), an autologous cell-based regenerative medicine company, today announced that affiliates of Boyalife Group have...

Read more

2 Dec

Cesca Receives Approval for Medicare Coverage

IDE Study Protocol Critical Limb Ischemia by SurgWerksTM-CLI Kit and VXP System (“CLIRST III”) Meets Requirements of Center for Medicare and Medicaid Services for Reimbursement RANCHO CORDOVA, Calif., Dec. 2, 2015 (GLOBE NEWSWIRE) — Cesca Therapeutics Inc. (KOOL), an autologous cell-based regenerative medicine company, today announced that it has received...

Read more

20 Nov

Cesca Therapeutics to Present at 2015 LD Micro Main Event

RANCHO CORDOVA, Calif., Nov. 20, 2015 (GLOBE NEWSWIRE) — Cesca Therapeutics Inc. (KOOL), an autologous cell-based regenerative medicine company, announced today that it will be presenting and meeting with investors at the 8th annual LD Micro Main Event on Wednesday, December 2 in Bel Air, California at the Luxe...

Read more

16 Nov

Cesca Therapeutics Reports First Quarter Fiscal Year 2016 Financial Results

Updates Investors on Financing Initiatives and the Status of Clinical Programs Management Will Hold a Conference Call Today at 2:00pm Pacific (5:00pm Eastern) RANCHO CORDOVA, Calif., Nov. 16, 2015 (GLOBE NEWSWIRE) — Cesca Therapeutics Inc. (KOOL), an autologous cell-based regenerative medicine company, today reported financial results for the first quarter...

Read more

12 Nov

Cesca Therapeutics to Present at 2015 World Alliance Forum in San Francisco

Regenerative Medicine: Let’s Talk Business! RANCHO CORDOVA, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) — Cesca Therapeutics Inc.(KOOL), an autologous cell-based regenerative medicine company, today announced that Robin Stracey, Chief Executive Officer and Dalip Sethi, Ph.D., Senior Clinical Scientist of Cesca Therapeutics will be presenting at the World Alliance Forum in...

Read more

Page 1 of 712345...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address